SG155782A1 - S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt - Google Patents

S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt

Info

Publication number
SG155782A1
SG155782A1 SG200802031-5A SG2008020315A SG155782A1 SG 155782 A1 SG155782 A1 SG 155782A1 SG 2008020315 A SG2008020315 A SG 2008020315A SG 155782 A1 SG155782 A1 SG 155782A1
Authority
SG
Singapore
Prior art keywords
iminoethyl
ethyl
amino
methyl
crystalline salt
Prior art date
Application number
SG200802031-5A
Other languages
English (en)
Inventor
Ahmad Sheikh
Lyle R Brostrom
Ann M Czyzewski
Vahid Zia
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of SG155782A1 publication Critical patent/SG155782A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26Separation; Purification; Stabilisation; Use of additives
    • C07C319/28Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
SG200802031-5A 2003-03-11 2004-03-04 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt SG155782A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45349603P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
SG155782A1 true SG155782A1 (en) 2009-10-29

Family

ID=32990778

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200802031-5A SG155782A1 (en) 2003-03-11 2004-03-04 S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt

Country Status (33)

Country Link
US (2) US20050038120A1 (pt)
EP (1) EP1603872B1 (pt)
JP (1) JP4794433B2 (pt)
KR (2) KR100927911B1 (pt)
CN (1) CN100460387C (pt)
AR (1) AR043521A1 (pt)
AT (1) ATE509909T1 (pt)
AU (1) AU2004220266B2 (pt)
BR (1) BRPI0408226A (pt)
CA (1) CA2518745C (pt)
CL (1) CL2004000472A1 (pt)
CO (1) CO5611122A2 (pt)
CY (1) CY1112461T1 (pt)
DK (1) DK1603872T3 (pt)
ES (1) ES2363001T3 (pt)
GT (1) GT200400040A (pt)
HK (1) HK1088301A1 (pt)
IL (1) IL170554A (pt)
MX (1) MXPA05008674A (pt)
NL (1) NL1025691C2 (pt)
NO (1) NO20054645L (pt)
NZ (1) NZ574218A (pt)
PA (1) PA8597701A1 (pt)
PE (1) PE20050309A1 (pt)
PL (1) PL1603872T3 (pt)
PT (1) PT1603872E (pt)
RU (1) RU2357953C2 (pt)
SG (1) SG155782A1 (pt)
SI (1) SI1603872T1 (pt)
TW (1) TWI352076B (pt)
UY (1) UY28229A1 (pt)
WO (1) WO2004080956A1 (pt)
ZA (1) ZA200506459B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6094101A (en) * 1999-03-17 2000-07-25 Tropian, Inc. Direct digital frequency synthesis enabling spur elimination
PL1793187T3 (pl) * 2004-09-21 2012-07-31 G & I Irtech S L Sposób i urządzenie do spiekania i/lub suszenia sproszkowanych materiałów z użyciem promieniowania podczerwonego

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403830B2 (en) * 2000-03-24 2002-06-11 Pharmacia Corporation Amidino compound and salts thereof useful as nitric oxide synthase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0765308T1 (en) * 1994-06-15 2000-08-31 The Wellcome Foundation Limited Enzyme inhibitors
AR031609A1 (es) * 2000-09-15 2003-09-24 Pharmacia Corp Derivados de acido 2-amino-2-alquil-3 heptenoico y heptinoico utiles como inhibidores de oxido nitrico sintetasa
AR031608A1 (es) * 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403830B2 (en) * 2000-03-24 2002-06-11 Pharmacia Corporation Amidino compound and salts thereof useful as nitric oxide synthase inhibitors

Also Published As

Publication number Publication date
MXPA05008674A (es) 2005-10-18
NL1025691A1 (nl) 2004-09-14
IL170554A (en) 2011-10-31
CA2518745C (en) 2010-10-19
HK1088301A1 (en) 2006-11-03
RU2357953C2 (ru) 2009-06-10
JP2006519838A (ja) 2006-08-31
NO20054645D0 (no) 2005-10-10
CY1112461T1 (el) 2015-12-09
NL1025691C2 (nl) 2006-06-30
KR20090048521A (ko) 2009-05-13
UY28229A1 (es) 2004-11-08
EP1603872B1 (en) 2011-05-18
BRPI0408226A (pt) 2006-03-01
SI1603872T1 (sl) 2011-07-29
ZA200506459B (en) 2006-11-29
KR20050107617A (ko) 2005-11-14
AR043521A1 (es) 2005-08-03
DK1603872T3 (da) 2011-07-18
CL2004000472A1 (es) 2005-05-13
TW200508185A (en) 2005-03-01
PL1603872T3 (pl) 2011-09-30
PE20050309A1 (es) 2005-05-04
US7767850B2 (en) 2010-08-03
EP1603872A1 (en) 2005-12-14
NZ574218A (en) 2009-11-27
PT1603872E (pt) 2011-06-07
PA8597701A1 (es) 2005-02-04
WO2004080956A1 (en) 2004-09-23
GT200400040A (es) 2005-01-14
NO20054645L (no) 2005-11-25
JP4794433B2 (ja) 2011-10-19
ES2363001T3 (es) 2011-07-18
CO5611122A2 (es) 2006-02-28
AU2004220266A1 (en) 2004-09-23
CA2518745A1 (en) 2004-09-23
CN1787993A (zh) 2006-06-14
KR100927911B1 (ko) 2009-11-19
TWI352076B (en) 2011-11-11
ATE509909T1 (de) 2011-06-15
AU2004220266B2 (en) 2010-08-19
US20050038120A1 (en) 2005-02-17
US20090215891A1 (en) 2009-08-27
CN100460387C (zh) 2009-02-11
RU2005125833A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
GEP20094625B (en) Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
PL360967A1 (en) Pharmaceutical compound containing donepezyl hydrochloride
HK1055425A1 (en) A crystalline form of perindopril tert-butylamine salt
IL164155A (en) Method for the preparation of crystalline quetiapine hemifumarate form i
HK1052502A1 (en) Hydrochloride salts of 5-Ä4-Ä2-(N-methyl-n-2-pyridyl) amino) ethoxyÜbenzylÜthiazolidine-2,4-dione
ZA200501418B (en) Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives
HK1171030A1 (en) Hydrochloride salts of a glycopeptide phosphonate derivative
AU2003214112A1 (en) Salts of nateglinide
AU2003298740A1 (en) Cyanomethyl derivatives as cysteine protease inhibitors
AU2003269747A1 (en) A stable aqueous composition of a peptide
PT1499587E (pt) Processo para síntese de sais de dissulfureto farmaceuticamente activos
HK1088301A1 (en) S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt ;
GB0211626D0 (en) Succinnylated fish gelatin for use as a blood plasma expander
AU2003220409A8 (en) Posterior chamber phakic lens
AU2003262264A1 (en) Agent for reducing side effects of diclofenac
HK1061857A1 (en) A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride
TW200503680A (en) S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-l-cysteine maleate form ii crystalline salt
ZA200409624B (en) Pharmaceutical salts of reboxetine
MXPA05009779A (es) Sal cristalina de salicilato de s-[2-[(1-iminoetil)amino]etil]-2-metil-l-cisteina monohidrato.
TW200504000A (en) Methods for selectively removing counterions from compounds and compounds derived from such methods
MXPA05009302A (es) Sal cristalina de maleato de s-[2-[(1-iminoetil)amino]etil]-2-metil-l-cisteina.
ITBO20040045A1 (it) Procedimento per l'applicazione di un inserto in una cinghia dentata
TW538975U (en) Improved structure of tool for plating of film
TW562369U (en) Structure of film holder
AU2002257244A1 (en) Improved dosage form of n-acetyl cysteine